Exelixis (EXEL)
(Delayed Data from NSDQ)
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.35 USD
+0.85 (2.98%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $29.38 +0.03 (0.10%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Zacks News
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Corcept's (CORT) Earnings and Sales Meet Estimates in Q4
by Zacks Equity Research
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Medicines Company (MDCO) Reports Q4 Loss, Revenues Slump Y/Y
by Zacks Equity Research
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
Will Mylan (MYL) Disappoint Investors This Earnings Season?
by Zacks Equity Research
During the Q4 earnings call, investors are expected to remain focused on the performance of Mylan's (MYL) EpiPen, newly launched drugs and the progress of the biosimilars pipeline.
Will Cabometyx Fuel Exelixis' (EXEL) Earnings in Q4 Again?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.
What's in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.
Key Factors to Influence Penumbra's (PEN) Earnings in Q4
by Zacks Equity Research
Penumbra (PEN) expects to gain from solid performance by neuro and peripheral vascular arms in Q4. Strong growth across all geographies is likely to drive the top line.
What's in Store for Veeva Systems (VEEV) in Q4 Earnings?
by Zacks Equity Research
Consistent focus on Subscription Services is likely to drive Veeva Systems (VEEV) in Q4.
Is a Beat in Store for Inogen (INGN) This Earnings Season?
by Zacks Equity Research
Strong product portfolio and a unique direct-to-consumer business model are expected to drive Inogen (INGN) in Q4.
Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
ACADIA (ACAD) is expected to provide further update on the progress of Nuplazid when it reports Q4 results on Feb 27.
What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?
by Zacks Equity Research
Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.
Can PBM Unit Drive Express Scripts' (ESRX) Earnings in Q4?
by Zacks Equity Research
Express Scripts (ESRX) expects Q4 results to show earnings growth on strength in PBM segment.
What to Expect From BioMarin (BMRN) This Earnings Season?
by Zacks Equity Research
BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q4. On the call, management is likely to comment on Brineura's launch progress and on the launch preparation for pegvaliase.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
by Zacks Equity Research
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Celgene Reports Positive Data on Dermatology Drug Otezla
by Zacks Equity Research
Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
by Zacks Equity Research
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.
Alkermes (ALKS) Beats Q4 Earnings, Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) tops earnings and sales estimates in the fourth quarter of 2017 on the back of strong growth of Vivitrol and Aristada. The company provided a decent outlook for 2018.
Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View
by Zacks Equity Research
Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.
Agios (AGIO) Q4 Loss Wider Than Expected, Revenues Slump Y/Y
by Zacks Equity Research
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
Prothena's (PRTA) Loss Narrows in Q4, Pipeline Progresses
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the fourth quarter as the company continued with its pipeline progress.
Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong
by Zacks Equity Research
Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.